Skip to content

Study · Non-randomized trial · 2018

4 results

Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.

Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C

Gastroenterology22 Nov 2017Cited by 102 (Europe PMC)

PMID29174926 (opens in a new tab)DOI10.1053/j.gastro.2017.11.023 (opens in a new tab)PepBankPUB-29174926
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In SBS with jejunostomy/ileostomy, teduglutide reduced support by 919 ± 644 mL/d versus 340 ± 436 mL/d with placebo (P = .0112).

    In plain wordsIn SBS with jejunostomy or ileostomy, teduglutide reduced support volume more than placebo.

    Peptide
    Teduglutide
    Outcome
    DecreaseSupport volume reduction in jejunostomy/ileostomy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Reduction in parenteral support volume, mean
    919 mL/d
    Teduglutide, group 1 (jejunostomy/ileostomy)
    Reduction in parenteral support volume, SD
    644 mL/d
    Teduglutide, group 1
    Reduction in parenteral support volume, mean
    340 mL/d
    Placebo, group 1
    Reduction in parenteral support volume, SD
    436 mL/d
    Placebo, group 1
    P value
    0.0112
    Teduglutide versus placebo, group 1

    Source sentences

    Summary
    The effects of teduglutide on absolute parenteral support volume were significantly greater in group 1 patients (reduction of 919 ± 644 mL/d), not only compared with patients given placebo (reduction of 340 ± 436 mL/d; P = .0112) but also compared with teduglutide-treated patients in group 2 (reduct…
    1 context sentence
    Summary · context
    We performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response.
  2. 02HumanObservational studyEfficacy outcome

    In SBS with intestinal failure, baseline parenteral support volume correlated with reduction during teduglutide treatment (r² = 0.61, P < .0001).

    In plain wordsIn SBS with intestinal failure, baseline support volume correlated with support reduction during teduglutide treatment.

    Peptide
    Teduglutide
    Outcome
    Direction not reportedBaseline support volume and support reduction
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Regression slope
    −0.387
    Baseline support volume
    Regression intercept
    90.0279
    Baseline support volume
    r squared
    0.61
    Correlation

    Source sentences

    Summary
    We correlated parenteral support volume reduction with teduglutide treatment and baseline parenteral support volume (y = -0.3870x + 90.0279, r2 = 0.61; P < .0001).
    1 context sentence
    Summary · context
    We performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response.
  3. 03HumanObservational studyEfficacy outcome

    In teduglutide-treated SBS, support reduction was 919 ± 644 mL/d with jejunostomy/ileostomy versus 355 ± 306 mL/d in group 2 (P = .0066).

    In plain wordsDuring teduglutide treatment, patients with jejunostomy or ileostomy had greater support reductions than patients with substantial colon continuity.

    Peptide
    Teduglutide
    Outcome
    IncreaseSupport reduction by bowel anatomy
    Study

    n: not reported in source

    Comparator
    Teduglutide-treated patients with ≥50% colon-in-continuity without stoma
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Reduction in parenteral support volume, mean
    919 mL/d
    Teduglutide, group 1
    Reduction in parenteral support volume, SD
    644 mL/d
    Teduglutide, group 1
    Reduction in parenteral support volume, mean
    355 mL/d
    Teduglutide, group 2
    Reduction in parenteral support volume, SD
    306 mL/d
    Teduglutide, group 2
    P value
    0.0066
    Group 1 versus group 2, teduglutide-treated

    Source sentences

    Summary
    The effects of teduglutide on absolute parenteral support volume were significantly greater in group 1 patients (reduction of 919 ± 644 mL/d), not only compared with patients given placebo (reduction of 340 ± 436 mL/d; P = .0112) but also compared with teduglutide-treated patients in group 2 (reduct…
    1 context sentence
    Summary · context
    We performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response.
  4. 04HumanObservational studyEfficacy outcome

    In SBS with other colon anatomies, teduglutide had an intermediate effect on parenteral support volume.

    In plain wordsIn SBS with other colon anatomies, teduglutide had an intermediate effect on support volume.

    Peptide
    Teduglutide
    Outcome
    Direction not reportedSupport response in other colon anatomies
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Teduglutide had an intermediate effect on patients in group 3.
    2 context sentences
    Summary · context
    and group 3, other colon anatomies)
    Summary · context
    We performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00798967

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Shiren = 8625 Nov 2008 to 25 Jan 2011

Short Bowel Syndrome

Trial pageClinicalTrials.govUpdated 3 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.